Medtronic Completes Regulatory Milestones Across Three Specialties with Stealth AXiS Robotic Platform in Five Months

Source:MedRobot

Reprint Requirements: Direct reprinting is permitted; please indicate the source at the beginning of the article.

June 8, 2026Medtronic announced that the Stealth AXiS™ surgical system has received CE marking in the European Union, with indications for ear, nose, and throat (ENT) surgery. This marks the fourth major regulatory milestone achieved by the platform in less than five months:

• February 13, 2026: FDA 510(k) clearance for spinal surgery (K253381)

• March 27, 2026: FDA 510(k) clearance for cranial and ENT surgery

• April 28, 2026: CE certified (spine and craniocerebral, under the EU MDR framework)

• June 8, 2026: Completed ENT European CE Certification

Stealth AXiS is now available in both the United States and Europe.Spine, Neurosurgery, ENTThree specialties, making it the only navigation robot integrated platform globally approved across three specialties in the two core markets.

# Technical Architecture: A Cross-Departmental Platform Leveraging Existing Assets

The underlying technology of Stealth AXiS is derived from two existing assets of Medtronic:

• Mazor Robotics: In 2018, Medtronic$1.64 billionAcquisition, Providing Robot-Guided Modules

• StealthStation Navigation System: Medtronic's proprietary assets, accumulated in ENT and cranial surgeries25+ YearsInstallation basics, continuously iterated since the launch of the LandmarX™ system in 1998

The new platform integrates planning, navigation, and robotic arms into a single system, adoptingFloor-Mounted Robotic ArmAdd configuration for the visualization console. Its FDA 510(k) documentation indicates that for spinal clinical applications, the mean error in 3D positioning accuracy is ≤2.0 mm, and the mean error in trajectory angular accuracy is ≤2.0 degrees.

Modular DesignThis constitutes the system’s primary value proposition: hospitals can deploy basic navigation capabilities on demand and subsequently add robotic modules (Stealth AXiS Autopilot), eliminating the need for a one-time, comprehensive procurement. For ENT indications, the system supports minimally invasive sinus surgery, skull base surgery, and balloon dilation procedures, and through its software architecture andGE HealthCare's bkActiv™ Intraoperative Ultrasound SystemConnect and access the Medtronic AiBLE™ smart ecosystem.

# Competitive Landscape: Four-Party Benchmarking in the ENT Navigation Submarket

ENT Surgical Navigation is a relatively concentrated but evolving market segment undergoing changes in ownership. According to industry data, Medtronic holds approximately18%-19%market share, with Stryker accounting for approximately 16%, followed closely by Brainlab, Zimmer Biomet, Siemens Healthineers, and others. ENT applications account for approximately of the overall surgical navigation system market16%。

The core difference between Medtronic Stealth AXiS and the aforementioned solutions lies in:Integrate the robotic execution end with the navigation planning end into a single system, whereas most existing ENT navigation platforms (including Stryker/Scopis and Integra/Acclarent) remain as standalone navigation devices without robotic arms.

# Business Deployment Logic: ASC Expansion and Partnership with Karl Storz

Medtronic’s deployment strategy for Stealth AXiS clearly targets two types of scenarios:Traditional Hospital Operating RoomandAmbulatory Surgery Center (ASC)ASC has become one of the primary directions for the shift in ENT surgical volume in recent years. Compared to hospitals, ASCs have lower tolerance for high equipment unit prices, large floor space requirements, and operational complexity; a modular architecture theoretically aligns well with the needs of this setting.

Just as the ENT CE certification was releasedFour days ago (June 4, 2026), Medtronic announced a partnership withKarl StorzStrategic Partnership: Integrating the Stealth AXiS ENT System with Karl Storz’s Endoscopic Instruments and Visualization Solutions for the U.S. Market to Streamline Procurement and Implementation in ENT Operating Rooms. The collaboration encompasses joint medical education, fellowship programs, and industry conference learning initiatives. As a core supplier in the ENT endoscopy field, Karl Storz enables Medtronic to simultaneously control...Navigation RobotandVisualized InstrumentsEntrance.

This aligns with Medtronic’s pathway in the spine sector: the AiBLE ecosystem has been integratedSiemens Healthineers(Announced partnership in September 2024, integrating Multitom Rax™ preoperative/postoperative imaging) andGE HealthCare(Intraoperative Ultrasound), external collaborations continue to expand, and platform value is gradually realized through ecosystem integration.

# Progress in Clinical Implementation

In late April 2026, Medtronic announced the completion of Stealth AXiS's# First Batch of Clinical Cases, involving spinal surgery. Dr. Joseph Osorio of the University of California, San Diego, commented, “This platform unifies preoperative planning with real-time intraoperative intelligence; the combination of AI-driven tools and LiveAlign dynamic motion detection represents a significant advancement in the precision and adaptability of spinal surgery.” Dr. Jeffrey Gum of Norton Healthcare stated, “In spinal surgery, real-time visualization of alignment and motion changes has transformed how procedures are performed—I can maintain adherence to the plan without interrupting my workflow.”

# Conclusion

The ENT CE certification of Stealth AXiS appears on the surface to be a routine regulatory advancement, but in essence, it is Medtronic"Cross-Departmental Platformization"A Key Strategic Move in the ENT Sector.

For industry observers, what deserves more attention is not “Medtronic has obtained another certification,” but rather:Will the integration of navigation and robotic execution into a single system alter the equipment procurement logic, clinical training pathways, and supply chain landscape in ENT operating rooms?Do existing pure navigation solutions need to be addressed in the product roadmap?

This introduces new variables for all participants.